Abstract 3743
Background
The identification of HER2 overexpression in a subset of gastric cancer (GC) patients represents a significant step forward in unveiling the molecular complexity of this disease. The predictive and prognostic value of HER2 amplification in advanced HER2 inhibitor-treated GC patients has been investigated. However, its predictive value in early stage resectable patients remains unclear. In this study we interrogated the correlation between HER2 copy number (CN) and disease-free survival (DFS).
Methods
We enrolled 98 treatment-naïve resectable (stage I-III) Chinese GC patients with HER2 overexpression assessed using IHC. Capture-based targeted sequencing using a panel consisting of 41 gastrointestinal cancer -related genes was performed on FFPE samples. Furthermore, we also investigated the correlation between HER2 CN and DFS. This cohort had 81 males and 17 females, with a median age of 64. 12, 62 and 24 patients had diffuse, intestinal and mixed GC respectively.
Results
Of the 98 HER2-overexpressed patients assessed using IHC, 91 had HER2 CN amplification assessed using next-generation sequencing, achieving 93% concordance. In addition, 10 had concurrent HER2 missense mutations, including 4 with S310X. All patients except for two had at least one concurrent mutation. The most commonly seen concurrent mutations were TP53, EGFR and PIK3CA, occurring in 85%, 13% and 12% patients, respectively. Furthermore, 23 patients had mutations in EGFR, MET, PDGFRA or KIT, which may participate in the activation of bypass pathways. We also revealed that patients with concurrent TP53 (p = 0.05) or PI3KCA (p = 0.02) mutations were significantly older than patients without. Next, dichotomous analysis was performed to investigate the association between HER2 CN and DFS. Stage I patients did not undergo adjuvant chemotherapy and all stage II-III patients underwent adjuvant chemotherapy. Our study revealed that patients with high HER2 CN had a significantly shorter DFS than patients with low HER2 CN (p = 0.002).
Conclusions
We elucidated the mutation spectrum of HER2-amplified resectable Chinese GC patients and the association between HER2 CN and DFS. Our study revealed the predictive value of HER2 CN and allowed us to further stratify HER2-positive patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4390 - Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)
Presenter: Sakti Chakrabarti
Session: Poster Display session 2
Resources:
Abstract
1025 - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging.
Presenter: Angela Lamarca
Session: Poster Display session 2
Resources:
Abstract
5813 - Is MGMT methylation a new therapeutic target for Biliary Tract Cancer?
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5839 - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.
Presenter: Patricia Pereira
Session: Poster Display session 2
Resources:
Abstract
4338 - Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: a post-hoc analysis of the SARAH trial
Presenter: Daniel Palmer
Session: Poster Display session 2
Resources:
Abstract
1700 - Second-line chemotherapy (SLC) in Patients with Advanced Biliary tract and Gallbladder Cancers (ABGC) Prolongs Survival: A Retrospective Population-based Cohort Study
Presenter: Adnan Zaidi
Session: Poster Display session 2
Resources:
Abstract
5562 - Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted dosimetry in the SARAH trial
Presenter: Neil Hawkins
Session: Poster Display session 2
Resources:
Abstract
1838 - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
Presenter: Naohiro Okano
Session: Poster Display session 2
Resources:
Abstract
3641 - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization
Presenter: Xiaolu Ma
Session: Poster Display session 2
Resources:
Abstract
2733 - The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).
Presenter: Francesco Caputo
Session: Poster Display session 2
Resources:
Abstract